Clinical Trials
Retina Associates of South Texas has a history of commitment to participating in clinical trials in order to provide our patients access to new, state-of-the-art therapeutic treatments. Our goal is to provide patients the opportunity to participate in clinical trials of new treatments for retinal diseases. We have partnered with leading pharmaceutical companies, the National Eye Institute and other clinical practices to seek solutions to many retinal conditions.
Participation in a clinical trial is completely voluntary. Eligibility for enrollment into a particular trial is determined through a screening process that varies from study to study. Because of the specific nature of your disease, you may not be eligible for participation. If you decide not to participate or are deemed ineligible, the physicians at Retina Associates will continue to care for your eyes and provide you with the highest standard of care available.
We strive to ensure that our study patients experience the best medical care possible. It is easy for patients to participate successfully in our studies and make informed decisions about their condition. If you are interested in being screened for one of our trials, please reach out to Jovan Garcia or Jaynee Baker at 210-615-7600.
CURRENT TRIALS
Age Related Macular Degeneration
Apellis Gale - A study of the investigational intravitreal injection pegcetacoplan in Geographic Atrophy seconday to Age-Related Macular Degeneration
Alkeus - A study of the investigational oral pills drug ALK-0012 in Geographic Atrophy seconday to Age-Related Macular Degeneration
RegenxBio (currently enrolling) - A study of the investigational Gene Therapy RGX-314 for patients with neovascular age-related macular degeneration
Golden - A study of the investigational subcutaneous drug IONIS-FB-LRX for the treatment of Geographic Atrophy secondary to Age-Related Macular Generation.
Shore (currently enrolling) - A study of the investigational intravitreal injection OPT-302 and ranibizumab for patients with neovascular age-related macular degeneration
Diabetic Macular Edema
Ocuterra DREAM (currently enrolling)- A study of the investigational drug OTT166 for the treatment of diabetic macular edema using topical drops only.
Kalahari (currently enrolling) - A study of the investigational intravitreal injection ETHR-149 vs the gold standard of Eylea For the treatment of diabetic macular edema.
Diabetic Retinopathy
Novartis Condor - A study of investigational drug, Brolucizumab every 4 weeks versus laser in adult patients with Visual impairment due to PDR (non-treatment naive)
Retinopathy of Prematurity
Butterfleye - Extension - A study to assess the efficacy and safety of intravitreal aflibercept compared to laser photocoagulation in patients with retinopathy of prematurity
PAST CLINICAL TRIALS
Diabetic Retinopathy
MacuSight DR-002
Alcon C-07-43
Genentech RIDE
Retina Vein Occlusion
Genentech BRAVO
Genentech CRUISE
Retinopathy of Prematurity
CRYO-ROP
LIGHT-ROP
ET-ROP
Age Related Macular Degeneration
Allergan SEQUOIA
Novartis HAWK and Hawk Extension
TOGA
Visudyne (verteporfin) for AMD
Macugen (pegaptanib) for AMD - LEVEL
Lucentis for AMD - ANCHOR, PIER, SAILOR
Genetech HARBOR
Graybug ALTISSIMO
Chengdu Panda
Novartis Talon
Ocular Tumors
Collaborative Ocular Melanoma Study